Mean change (± standard deviation) from Visit 1 to Visit 4 in maternal (a) RBC DHA (wt% TFA) (p < 0.0001 in favor of MMS), (b) omega 3 index (p < 0.0001 in favor of MMS), and (c) calcidiol (25-hydroxyvitamin D) (p = 0.0122 in favor of MMS) (per protocol population; LOCF approach). Visit 1: Screening (GA Week 11/14); Visit 3: GA Week 24/26; Visit 4: GA Week 34/36. DHA, docosahexaenoic acid; GA, gestational age; LOCF, last observation carried forward; MMS, multiple micronutrients and DHA supplementation; RBC, red blood cells; SD, standard deviation; TFA, total fatty acids; wt, weight.